Collection of Health-Economic Data Alongside Clinical Trials: Is There a Future for Piggyback Evaluations?
- 1 January 2005
- journal article
- review article
- Published by Elsevier BV in Value in Health
- Vol. 8 (1), 67-79
- https://doi.org/10.1111/j.1524-4733.2005.03065.x
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical resultsOsteoarthritis and Cartilage, 2002
- A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic resultsOsteoarthritis and Cartilage, 2002
- Design Issues for Conducting Cost-Effectiveness Analyses Alongside Clinical TrialsAnnual Review of Public Health, 2001
- Introducing economic and quality of life measurements into clinical studiesAnnals of Medicine, 2001
- The problem of protocol driven costs in pharmacoeconomic analysis.PharmacoEconomics, 1998
- Initial Antidepressant Choice in Primary CareJAMA, 1996
- Cost-effectiveness comparisons using “real world” randomized trials: The case of new antidepressant drugsJournal of Clinical Epidemiology, 1995
- A randomized trial to assess effectiveness and cost in clinical practice: Rationale and design of the cholesterol reduction intervention study (CRIS)Controlled Clinical Trials, 1995
- Economic Analysis Alongside Clinical Trials: Revisiting the Methodological IssuesInternational Journal of Technology Assessment in Health Care, 1991
- Explanatory and pragmatic attitudes in therapeutical trialsJournal of Chronic Diseases, 1967